| Symbol | PBIMF |
|---|---|
| Name | BLS PHARMACEUTICALS LIMITED |
| Sector | UNDEFINED |
| Region | Oceania |
| Industry | - |
| Address | 2000 Australia NSW Suite 506, Level 5 50,Clarence Street |
| Telephone | +61 2 9078 8180 |
| Fax | — |
| — | |
| Website | https://bioxyne.com/ |
| Incorporation | AU |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
| CIK | — |
| Description | Bioxyne Limited, a life sciences and consumer health products company, manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines in the United Kingdom, Japan, Europe, and Australia. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, vitamins, manuka honey, skin care products, and mushroom complexes. It develops various functional food products, such as ingredients; and lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products. The company also provides product research and development services, and telemedicine services. In addition, it operates BLS Clinics, a telehealth platform. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Additional info from OTC: |
No news found.